Latest news with #CLEP
Yahoo
15-05-2025
- Business
- Yahoo
‘Real world' experiences can yield college credit for Utah Valley University students
More than a third of the students at Utah Valley University — the state's largest college — are 25 or older. That means a sizable chunk of UVU's student body are likely bringing to the classroom an abundance of 'real world' experience in, say, business, entrepreneurship, management or land surveying. School leaders say they value such experience — and that they're eager to reward eligible students possessing a robust 'experience-resume' with college credit and a speedier path to graduation. As in the past, students at the Orem institution can continue to earn college credit by passing, say, CLEP tests and standardized language tests. But UVU is also broadening its Credit for Prior Learning program to include credit-granting opportunities in business, construction management, criminal justice, culinary arts, nutrition, health sciences and several other professional areas. 'We're reimagining what it means to be a learner,' Colleen Sorensen, UVU's director of CPL and Student Assessment Services, told the Deseret News. 'We're shifting our culture to honor and assess the skills and the knowledge that students bring with them, because we realize that learning happens everywhere. 'We want college-level learning to be recognized.' The aim of expanding UVU's Credit for Prior Learning program is simple: increase graduation rates while providing a faster route to career advancement. 'CPL accelerates the time to the degree and helps the student significantly,' added Sorensen. It's ideal for many military veterans, working professionals, stay-at-home parents and returning college students. Students who served religious missions might also be candidates for the program if they have acquired skills in a foreign language offered at the university and/or other life experiences that fit within a specific academic program and include college-level learning. Credit for Prior Learning credit is awarded to matriculated UVU students who demonstrate — through a prior-learning assessment — that their 'real world' learning meets college-level competencies, according to the school's program site. It's a way for eligible students to receive credit for skills acquired on the job or through, say, professional or military training. And the CPL's formal assessment process ensures that the integrity and academic standards of UVU's specific academic programs are maintained, according to Sorensen. Credit for prior learning is awarded by demonstrating proficiency in a particular field — including professional certifications, third party evaluations, standardized exams, institutional exams, individualized assessments and student-submitted portfolios. For example, according to UVU, individuals who have earned Certiport Microsoft office specialist certifications may receive credit for information management coursework. Military veterans and public safety professionals can apply prior training toward emergency services degrees. In digital media, portfolios from professionals in animation, digital cinema, or web development can be assessed for credit. Each UVU department participating in the credit program will award credit within the context of their specific mission, student needs and academic program, according to UVU. Credentialed faculty in each discipline will establish the course criteria and assess fulfillment to determine credit awarded. Program credits may be applied toward courses in a certificate of completion, AA, AS, AAS degree, BS degree and BA degree programs only for the purpose of satisfying graduation requirements, according to the university. The number of credit hours that may be awarded will likely depend upon the certificate or degree being pursued by the student. UVU's credit program is also available to graduate students, noted Sorensen. UVU's program website includes an online 'self-assessment checklist' to help would-be applicants determine if the program is a viable option. The checklist includes questions such as: 'Have I had at least three years of experience in the field/subject area?'; 'Do I understand both the practical and theoretical applications of the course?'; and 'Have I managed other people at work or a volunteer organization?' If the program appears to be a promising option, interested students can complete an online questionnaire and begin their application process. An assessment team will then review the student's questionnaire and provide additional information. While there's no guarantee that a student's application will be approved, Sorensen said the program has already proven rewarding for a significant number of UVU students. 'Last semester, about 62% of the program requests were awarded — and we would like to see that number increase,' she said.
Business Wire
29-04-2025
- Health
- Business Wire
Evvy Partners with Leading Fertility Clinics to Launch Landmark Study Uncovering the Role of the Vaginal Microbiome in IVF Outcomes
NEW YORK--(BUSINESS WIRE)--Evvy, a pioneering women's health startup focused on the vaginal microbiome, today announced the launch of a landmark clinical study exploring the link between the vaginal microbiome and in vitro fertilization (IVF) outcomes. This will be the first-ever study using a validated, commercially available vaginal microbiome test to uncover potential microbial markers linked to IVF success. The study was designed in collaboration with leading fertility doctors including Dr. David Sable (Life Sciences), Dr. Peter Klatsky (Spring Fertility), Dr. Sara Vaughn (HRC Fertility), and Dr. Eduardo Hariton (Reproductive Science Center), alongside Evvy's Chief Science Officer, Pita Navarro, and Chief Medical Officer, Dr. Kate McLean. Together, they aim to identify the specific vaginal markers associated with IVF outcomes. The study is already live with multiple clinics across the country with significant interest from fertility clinics and research institutions to join. Clinics or researchers interested in becoming study sites are encouraged to reach out to participate in this growing collaborative effort to advance the science of fertility. 'Despite doing everything 'right,' many IVF patients still face heartbreaking failures without clear explanations,' says Dr. Kate McLean, Chief Medical Officer at Evvy. 'This study could fundamentally enhance our understanding of why some cycles fail — and unlock a new, proactive tool for patients and providers to improve outcomes.' With roughly 1 in 8 couples facing infertility and average IVF success rates remaining around 30–40% per cycle, there's a clear and urgent need for more predictive and preventive insights in fertility care. While early research has linked vaginal microbiome disruptions to IVF failure, recurrent pregnancy loss, and preterm birth, those insights have yet to be translated into clinical practice at scale. With this study, Evvy hopes to leverage their unique testing and data platform to finally bridge the gap between research and patient care — providing answers where they didn't previously exist. Evvy's test is CLIA, CAP, and CLEP certified, and validation of the test methodology was published in the peer-reviewed Diagnostics journal. The test can detect 700+ microbes from a single, at-home swab. Through Evvy's platform, they've built the world's largest dataset on the vaginal microbiome and created a proprietary database with hundreds of novel genomes. Through this proprietary platform, Evvy is uniquely positioned to map key microbial signatures to clinical outcomes. 'Despite decades of progress in reproductive medicine, there's still so much we're learning about the underlying biology that contributes to IVF outcomes,' says Pita Navarro, Co-Founder and Chief Science Officer of Evvy. 'The vaginal microbiome has been consistently overlooked in fertility research, even as evidence grows around its role in reproductive outcomes. With this study, we hope to generate new insights that deepen our understanding and lay the scientific foundation for future tools to help doctors and their patients make more personalized, informed decisions about care.' The launch of this study builds on Evvy's recent release of fertility-focused insights, which enable users to assess and improve their vaginal microbiome before trying to conceive, undergoing IVF, or exploring causes of unexplained infertility. The company aims to build solutions based on what science already knows—and do the research where it has been overlooked. This study is the first of many in Evvy's pipeline to validate the power of vaginal microbiome testing in predicting a variety of women's health outcomes throughout the lifespan. About Evvy Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy's groundbreaking Vaginal Health Test is the world's only certified, peer-reviewed vaginal microbiome test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways and 1-1 coaching, Evvy provides over 50,000 women with data-driven, personalized healthcare for vaginal infections, fertility, menopause, and more. Evvy has built the world's largest dataset on the vaginal microbiome, and they are pioneering novel research to transform female health outcomes.
Business Wire
22-04-2025
- Health
- Business Wire
Invivoscribe's LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM's ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes. Following a rigorous review by the Clinical Laboratory Evaluation Program (CLEP), the Department of Health has determined that LabPMM meets the required standards and granted approval to offer the FLT3 ITD MRD Assay in New York State. This approval underscores the assay's robust analytical performance and clinical utility in the detection of MRD in patients with FLT3 ITD-mutated AML. "This milestone reflects our commitment to improve patient lives with precision diagnostics," said Jordan Thornes, V.P. Global Clinical Operations at LabPMM ®. "With New York state's approval, we are immediately able to extend access to this important test to clinicians and patients throughout one of the nation's largest and most rigorously regulated laboratory testing markets." The FLT3 ITD MRD assay is a targeted, highly sensitive next-generation sequencing (NGS) assay that detects and tracks internal tandem duplication (ITD) mutations in the fms-like tyrosine kinase 3 (FLT3) gene at an allele sensitivity of 5 x 10 -5. FLT3 ITD mutations are the most prevalent mutations found in AML and are characterized by an aggressive phenotype with a high prevalence of relapse. 1,2 Detection of residual FLT3 ITD allows clinicians to identify patients that can benefit from continuation or modification of treatment and predict clinical outcomes. 1,2,3 For more information about the FLT3 ITD MRD Assay and LabPMM's full test menu, please visit or contact us at inquiry@ and follow us on LinkedIn. About Invivoscribe Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the US, Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. Dillon, L., et al. JAMA. 2023;329(9):745-755. Dillon, L., et al. JAMA Oncol. 2024;10(8):1104-1110. Levis, MJ et al. (2018) Blood Advances. 2: 825-831.
Yahoo
22-04-2025
- Business
- Yahoo
Invivoscribe's LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay
SAN DIEGO, April 22, 2025--(BUSINESS WIRE)--Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM's ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes. Following a rigorous review by the Clinical Laboratory Evaluation Program (CLEP), the Department of Health has determined that LabPMM meets the required standards and granted approval to offer the FLT3 ITD MRD Assay in New York State. This approval underscores the assay's robust analytical performance and clinical utility in the detection of MRD in patients with FLT3 ITD-mutated AML. "This milestone reflects our commitment to improve patient lives with precision diagnostics," said Jordan Thornes, V.P. Global Clinical Operations at LabPMM®. "With New York state's approval, we are immediately able to extend access to this important test to clinicians and patients throughout one of the nation's largest and most rigorously regulated laboratory testing markets." The FLT3 ITD MRD assay is a targeted, highly sensitive next-generation sequencing (NGS) assay that detects and tracks internal tandem duplication (ITD) mutations in the fms-like tyrosine kinase 3 (FLT3) gene at an allele sensitivity of 5 x 10-5. FLT3 ITD mutations are the most prevalent mutations found in AML and are characterized by an aggressive phenotype with a high prevalence of relapse. 1,2 Detection of residual FLT3 ITD allows clinicians to identify patients that can benefit from continuation or modification of treatment and predict clinical outcomes. 1,2,3 For more information about the FLT3 ITD MRD Assay and LabPMM's full test menu, please visit or contact us at inquiry@ and follow us on LinkedIn. About Invivoscribe Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the US, Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. Dillon, L., et al. JAMA. 2023;329(9):745-755. Dillon, L., et al. JAMA Oncol. 2024;10(8):1104-1110. Levis, MJ et al. (2018) Blood Advances. 2: 825-831. View source version on Contacts inquiry@ Sign in to access your portfolio
Yahoo
18-02-2025
- Health
- Yahoo
ClearNote Health Earns Approval for Avantect® Pancreatic Cancer Test from New York State Department of Health
Physicians in New York can now order the highly sensitive blood test designed to detect pancreatic cancer far earlier than conventional approaches SAN DIEGO, February 18, 2025--(BUSINESS WIRE)--ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved its Avantect® Pancreatic Cancer Test. With this approval, clinicians in New York State can now order this highly sensitive blood test, which is designed to detect the biological signals of pancreatic cancer in its earliest stages for patients with known risk factors. "New York State is well known for its rigorous, patient-focused quality standards for laboratory-developed tests. This approval is another critical milestone for ClearNote Health, further validating our ongoing commitment to excellence in our tests and in our clinical laboratory services," said Dave Mullarkey, CEO at ClearNote Health. "We are quickly transforming the patient care paradigm with a proprietary, epigenomics-based approach that allows clinicians to detect pancreatic cancer at a more treatable stage so patients can enjoy longer, healthier lives." While early detection has vastly improved survival rates for other types of cancer, pancreatic cancer is often diagnosed at an advanced metastatic stage when patients have a five-year survival rate as low as 3%.1 The Avantect Pancreatic Cancer Test is for patients at high risk of pancreatic cancer, including those newly diagnosed with type 2 diabetes who are at least 50 years old, as well as those with a family history and/or a genetic predisposition. The test was designed to detect pancreatic cancer in its earliest stages by profiling the epigenomic biomarker 5-hydroxymethylcytosine (5hmC) in cell-free DNA and combining that data with other genomic information. Unlike conventional methods, ClearNote's approach leverages the latest advances in machine learning and bioinformatics to provide a deeper understanding of the underpinnings of cancer development with unprecedented clarity to inform the next steps in a patient care pathway. For more information about the Avantect Pancreatic Cancer Test, please visit The NYSDOH CLEP regulates and oversees laboratories that accept clinical specimens originating in New York State. It seeks to ensure the accuracy and reliability of test results in clinical laboratories located in or accepting specimens from New York State. The ClearNote Health Laboratory now has its NYSDOH permit, as well as its CLIA certification and CAP accreditation. About ClearNote Health ClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company's patented core Virtuoso® epigenomics platform builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample. The company's highly sensitive, noninvasive Avantect® Pancreatic and Ovarian diagnostic tests are designed to identify cancers in high-risk patient populations far earlier than conventional approaches, when patients are most likely to benefit from treatment. ClearNote Health's headquarters and CLIA-certified, CAP-accredited laboratory are located in San Diego. For more information, visit or follow the company on X or LinkedIn. ClearNote Health, the ClearNote Health logo, Avantect, and Virtuoso are registered trademarks of ClearNote Health. References 1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019 Feb;10(1):10-27. doi: 10.14740/wjon1166. View source version on Contacts Media Contact Andrew Noble415-722-2129andrew@ Sign in to access your portfolio
